Publications
511
Citations
19,403
Est. group size
~6
Recurring co-author estimate
Active years
43
Publishing since 1983
Typically publishes in teams of ~8 · 20% small-team papers (≤3 authors) · across 44 venues
- Sparsentan (SPAR) vs. Irbesartan (IRB) in Pediatric Patients with FSGS in the Phase 3 DUPLEX Trial
Journal of the American Society of Nephrology · 2025
- Estimating the Benefits of Proteinuria Reduction on Kidney Failure Risk in the DUPLEX Study Using an Aligned FSGS Cohort from the UK RaDaR Registry
Journal of the American Society of Nephrology · 2025
- Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy
Expert Review of Clinical Immunology · 2024
- Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety
Kidney Medicine · 2024
- Sparsentan (SPAR) in Pediatric Patients with Rare Proteinuric Kidney Disease: Preliminary Findings from the EPPIK Study
Journal of the American Society of Nephrology · 2024
- WCN24-774 PRELIMINARY FINDINGS FROM THE PHASE 2 EPPIK STUDY OF SPARSENTAN IN PEDIATRIC PATIENTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES
Kidney International Reports · 2024
- Late Clinical-Stage Candidate Rilparencel's Effect on Kidney Function and Biological Pathways in a Type 2 Diabetes and CKD Patient Subset
Journal of the American Society of Nephrology · 2024
- The genetic landscape and clinical spectrum of nephronophthisis and related ciliopathies
Kidney International · 2023
- Kidney Considerations in Pediatric Obesity
Current Obesity Reports · 2023
- Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial
Kidney International Reports · 2023
- Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
International Journal of Nephrology and Renovascular Disease · 2023
- Organic Pollutant Exposure and CKD: A Chronic Renal Insufficiency Cohort Pilot Study
Kidney Medicine · 2023
- Maximizing the value of the open label extension phase of randomized clinical trials
Journal of Nephrology · 2023
- Status of current trials and potential future trials with sparsentan
Expert Opinion on Emerging Drugs · 2023
- Review for "Urinary SPP1 has potential as a non-invasive diagnostic marker for focal segmental glomerulosclerosis"
2023
- Journal of the American Society of Nephrology×25
- Kidney International Reports×19
- UNC Libraries×9
- Kidney International×8
- Kidney Medicine×7
- Myda Khalid
Medicine · Indiana University
- Laura Mariani
Medicine · University of Michigan
- Salem Almaani
Medicine · The Ohio State University
- Mahmoud Kallash
Medicine · The Ohio State University
- Takaya Ozeki
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile